Humana Inc. has added Lifeward Ltd.’s ReWalk 7 personal exoskeleton to its Medicare Advantage benefit portfolio, making it the second national Medicare Advantage plan to cover the device after UnitedHealthcare. The move expands coverage for individuals with spinal cord injuries across the United States.
The decision aligns with Humana’s long‑standing commitment to value‑based care, which seeks to improve health outcomes while containing costs. By covering a technology that enables patients to stand, walk, and navigate stairs, Humana is positioning itself as a leader in innovative therapies that can reduce long‑term care needs and improve quality of life for its members.
The addition is expected to increase Humana’s reimbursement revenue from the exoskeleton and enhance member satisfaction for those with mobility limitations. It also strengthens Humana’s competitive position in the Medicare Advantage market, where plans that offer unique, technology‑driven benefits can differentiate themselves to attract and retain enrollees.
Lifeward’s ReWalk 7 benefits from a formal Medicare reimbursement pathway that was established in 2024, and the coverage by major plans signals broader payer acceptance of personal exoskeletons. The approval is a key milestone for Lifeward, which has been expanding its product portfolio to include the ReStore exo‑suit and AlterG anti‑gravity systems.
No immediate market reaction has been reported following the announcement. The coverage decision is part of Humana’s broader strategy to enhance value‑based care offerings and support its long‑term growth objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.